[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2872482T3 - Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm) - Google Patents

Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)

Info

Publication number
PL2872482T3
PL2872482T3 PL13817231T PL13817231T PL2872482T3 PL 2872482 T3 PL2872482 T3 PL 2872482T3 PL 13817231 T PL13817231 T PL 13817231T PL 13817231 T PL13817231 T PL 13817231T PL 2872482 T3 PL2872482 T3 PL 2872482T3
Authority
PL
Poland
Prior art keywords
sarm
androgen receptor
receptor modulator
breast cancers
selective androgen
Prior art date
Application number
PL13817231T
Other languages
English (en)
Inventor
James T. Dalton
Mitchell S. Steiner
Ramesh Narayanan
Sunjoo Ahn
Original Assignee
Oncternal Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics, Inc. filed Critical Oncternal Therapeutics, Inc.
Publication of PL2872482T3 publication Critical patent/PL2872482T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13817231T 2012-07-13 2013-03-07 Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm) PL2872482T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261671366P 2012-07-13 2012-07-13
US201261726274P 2012-11-14 2012-11-14
EP13817231.7A EP2872482B1 (en) 2012-07-13 2013-03-07 A method of treating breast cancers with selective androgen receptor modulator (sarm)
PCT/US2013/029667 WO2014011220A2 (en) 2012-07-13 2013-03-07 A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms)

Publications (1)

Publication Number Publication Date
PL2872482T3 true PL2872482T3 (pl) 2021-03-08

Family

ID=49914508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13817231T PL2872482T3 (pl) 2012-07-13 2013-03-07 Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)

Country Status (20)

Country Link
US (1) US9604916B2 (pl)
EP (2) EP2872482B1 (pl)
JP (3) JP6226978B2 (pl)
KR (2) KR102122941B1 (pl)
CN (3) CN104754939A (pl)
AU (3) AU2013203600C1 (pl)
CA (1) CA2879049C (pl)
CY (1) CY1123542T1 (pl)
DK (1) DK2872482T3 (pl)
ES (1) ES2818915T3 (pl)
HR (1) HRP20201463T1 (pl)
HU (1) HUE052574T2 (pl)
IL (1) IL236681B (pl)
IN (1) IN2015DN01046A (pl)
LT (1) LT2872482T (pl)
MX (2) MX2015000572A (pl)
PL (1) PL2872482T3 (pl)
PT (1) PT2872482T (pl)
RU (2) RU2717835C2 (pl)
WO (1) WO2014011220A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
JP5958483B2 (ja) * 2013-07-31 2016-08-02 株式会社村田製作所 電力増幅モジュール
RU2691652C2 (ru) * 2014-10-16 2019-06-17 ДжиТиИкс, ИНК. Способы лечения урологических нарушений с применением селективных модуляторов андрогеновых рецепторов
SG11201703279XA (en) 2014-10-22 2017-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
DK3283058T3 (da) * 2015-04-16 2023-02-13 Novartis Ag Ribociclib-tablet
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA2983403A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP2018513179A (ja) 2015-04-21 2018-05-24 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンド及びその使用方法
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA3002562A1 (en) * 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN112679495B (zh) 2016-04-01 2023-03-28 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN109310664A (zh) * 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP4455146A2 (en) * 2017-06-29 2024-10-30 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
MX2021011826A (es) * 2019-03-28 2021-12-10 Essa Pharma Inc Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
WO2020243373A1 (en) * 2019-05-29 2020-12-03 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
JP2022535827A (ja) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
AU2021227228A1 (en) * 2020-02-25 2022-09-22 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
US20230172897A1 (en) * 2021-12-02 2023-06-08 Veru, Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
WO2023172891A2 (en) * 2022-03-07 2023-09-14 Baylor College Of Medicine Biomarkers for combination therapy for er+ breast cancer
WO2023244059A1 (en) * 2022-06-15 2023-12-21 Ildong Pharmaceutical Co., Ltd. Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds
WO2024138077A1 (en) * 2022-12-21 2024-06-27 Duke University Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
JPH03502329A (ja) 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
ATE113607T1 (de) 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
AU1687395A (en) 1994-01-21 1995-08-08 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
ZA953976B (en) 1994-05-19 1996-01-19 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
WO1998027986A1 (en) 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
PL203771B1 (pl) 1998-07-06 2009-11-30 Bristol Myers Squibb Co Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
ES2277853T3 (es) 1999-10-14 2007-08-01 Kaken Pharmaceutical Co., Ltd. Derivados de tetrahidroquinolina.
IL148192A0 (en) 1999-10-14 2002-09-12 Bristol Myers Squibb Co Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure
WO2001028990A2 (en) 1999-10-19 2001-04-26 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
CN1413188A (zh) 1999-10-27 2003-04-23 诺贝克斯公司 基本纯的比卡鲁胺合成中中间体的拆分
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2625201A (en) 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
WO2002000617A2 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20070173546A1 (en) 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
CN1230418C (zh) 2000-08-24 2005-12-07 田纳西大学研究公司 选择性雄激素受体调节剂及其使用方法
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
EP1325914A4 (en) 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DE60239207D1 (de) 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
JP2005515988A (ja) 2001-11-29 2005-06-02 ジーティーエックス・インコーポレイテッド 骨粗鬆症を引き起こすアンドロゲン欠乏の予防及び治療
US20070161608A1 (en) 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
CA2469340A1 (en) 2001-12-06 2003-06-19 Gtx Inc. Treating muscle wasting with selective androgen receptor modulators
AU2003207717B9 (en) 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
PT1480634E (pt) 2002-02-07 2011-10-12 Univ Tennessee Res Foundation Moduladores selectivos do receptor do androgénio (sarms) para o tratamento da hiperplasia benigna da próstata
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
KR101088352B1 (ko) 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
MXPA04009460A (es) 2002-02-28 2006-04-27 Univ Tennessee Res Foundation Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos.
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
IL163743A0 (en) 2002-02-28 2005-12-18 Univ Tennessee Res Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
IL163825A0 (en) 2002-03-13 2005-12-18 Merck & Co Inc Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
TW200407280A (en) 2002-06-17 2004-05-16 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
EP1558232A4 (en) 2002-10-15 2008-07-02 Gtx Inc TREATMENT OF FAT SUPPORT WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
CN1726034A (zh) 2002-10-15 2006-01-25 田纳西大学研究基金会 亚甲基桥连的选择性雄激素受体调节剂及其应用方法
US20040265916A1 (en) 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
AU2003287076C1 (en) 2002-10-15 2010-03-04 University Of Tennessee Research Foundation Heterocyclic selective androgen receptor modulators and methods of use thereof
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US20140011774A1 (en) 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7199110B2 (en) 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
EP1592658B1 (en) 2003-01-13 2013-04-24 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
WO2004066922A2 (en) * 2003-01-22 2004-08-12 Gtx Inc. A method of treating breast cancer with androgen receptor antagonists
EP1594490A4 (en) * 2003-01-22 2006-03-22 Gtx Inc TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM)
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
CN1325506C (zh) 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
AU2004272004B2 (en) 2003-09-10 2009-01-22 Merck Sharp & Dohme Corp. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
SI1696909T1 (sl) 2003-09-12 2008-02-29 Serono Lab Derivati benzotiazola za zdravljenje diabetesa
EP1673376A4 (en) 2003-10-14 2010-06-23 Gtx Inc TREATMENT OF BONE DISEASES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
US20050137172A1 (en) * 2003-10-15 2005-06-23 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
TW200523235A (en) 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005060647A2 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
PT1756096E (pt) 2004-05-03 2009-10-16 Hoffmann La Roche Derivados de indolilo como moduladores do receptor x do fígado
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
CA2543827C (en) 2004-06-07 2010-03-09 James T. Dalton Selective androgen receptor modulators and methods of use thereof
US20130034562A1 (en) 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
MX2007000606A (es) 2004-07-14 2007-06-25 Johnson & Johnson Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
CA2621189A1 (en) 2005-08-31 2007-03-08 James T. Dalton Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
WO2007053503A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
JP2009518286A (ja) 2005-11-01 2009-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしてのジヒドロイソインドロン
CN102351732B (zh) 2005-11-28 2014-10-29 Gtx公司 核受体结合剂
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
EP1801140A1 (en) 2005-12-22 2007-06-27 Mnemoscience GmbH Macro-diacrylate
EP3056196A1 (en) * 2006-03-22 2016-08-17 SynCore Biotechnology CO., LTD Treatment of triple receptor negative breast cancer
BRPI0713179A2 (pt) * 2006-07-12 2012-03-27 Univ Tennessee Res Foundation processo para substituição e uso de compostos substitutos de acilanilidea
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
KR20160020584A (ko) 2007-01-22 2016-02-23 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
HUE036762T2 (hu) 2007-09-11 2018-07-30 Gtx Inc A szelektív androgén modulátor (R) vagy (S)-N-(4-ciano-3-(trifluor-metil)-fenil-3-(4-ciano-fenoxi)-2-hidroxi-2-metil-propánamid kristályos polimorfja
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CA2807557C (en) * 2009-08-06 2019-09-17 Partha S. Ray Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
MX2012004624A (es) 2009-10-23 2012-08-23 Panacela Labs Inc Metodos para tratar canceres positivos para el receptor de androgenos.
EP2523556A4 (en) 2010-01-11 2013-08-28 Gtx Inc METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)

Also Published As

Publication number Publication date
EP2872482B1 (en) 2020-07-08
AU2013203600C1 (en) 2016-11-24
LT2872482T (lt) 2020-12-28
RU2015104780A (ru) 2016-08-27
WO2014011220A2 (en) 2014-01-16
EP2872482A4 (en) 2016-03-30
AU2018201450B2 (en) 2019-06-13
HUE052574T2 (hu) 2021-05-28
IL236681B (en) 2021-04-29
JP2018168201A (ja) 2018-11-01
MX2015000572A (es) 2015-09-23
KR20150038085A (ko) 2015-04-08
RU2648959C2 (ru) 2018-03-28
US9604916B2 (en) 2017-03-28
CA2879049A1 (en) 2014-01-16
PT2872482T (pt) 2020-09-22
CY1123542T1 (el) 2022-03-24
CN110840870A (zh) 2020-02-28
CN108143728A (zh) 2018-06-12
IN2015DN01046A (pl) 2015-06-26
AU2013203600B2 (en) 2016-03-03
JP6386120B2 (ja) 2018-09-05
AU2013203600A1 (en) 2014-01-30
CN104754939A (zh) 2015-07-01
CA2879049C (en) 2021-02-23
JP6759290B2 (ja) 2020-09-23
KR102122941B1 (ko) 2020-06-15
RU2017141776A3 (pl) 2019-02-13
KR20200069394A (ko) 2020-06-16
DK2872482T3 (da) 2020-09-21
JP2017101088A (ja) 2017-06-08
ES2818915T3 (es) 2021-04-14
WO2014011220A3 (en) 2015-03-05
JP6226978B2 (ja) 2017-11-08
MX2020009725A (es) 2020-10-08
EP2872482A2 (en) 2015-05-20
RU2717835C2 (ru) 2020-03-26
AU2016203696A1 (en) 2016-06-23
RU2017141776A (ru) 2019-02-13
IL236681A0 (en) 2015-02-26
AU2016203696B2 (en) 2017-11-30
US20140018433A1 (en) 2014-01-16
JP2015522069A (ja) 2015-08-03
KR102238970B1 (ko) 2021-04-09
AU2018201450A1 (en) 2018-03-22
HRP20201463T1 (hr) 2021-04-02
EP3733170A1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
LT2872482T (lt) Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
HK1258404A1 (zh) 雄激素受體表達的調節
GB2503627B (en) Downhole apparatus
EP2694053A4 (en) SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF DIABETES
HK1212830A1 (zh) 種協同小區的探測參考信號資源配置方法及裝置
HK1208709A1 (en) A method of screening for colorectal cancer
GB2505559B (en) Subsea deployed apparatus and method
EP2939642A4 (en) METHOD AND DEVICE FOR SUPPLYING POWDER
GB201201379D0 (en) Method and apparatus for configuring a resource allaocation
HK1208867A1 (en) Indolecarbonitriles as selective androgen receptor modulators
IL231440A0 (en) Selective androgen receptor modulators
IL239076B (en) Modulators and selective androgen receptor
EP2849389A4 (en) METHOD AND DEVICE FOR ASSIGNING BANDWIDTH RESOURCES
GB201314844D0 (en) Carrier apparatus
GB201314017D0 (en) Carrier Apparatus